{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:56:00Z","timestamp":1783061760531,"version":"3.54.6"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"45","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Environ Sci Pollut Res"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11356-022-22345-w","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T21:02:32Z","timestamp":1659819752000},"page":"67685-67703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic"],"prefix":"10.1007","volume":"29","author":[{"given":"Ishnoor","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-7708","authenticated-orcid":false,"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vetriselvan","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj Kumar","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendran","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed Ghaleb","family":"Dailah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M.","family":"Alsubayiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Aleya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"22345_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","volume":"24","author":"SM Adnan","year":"2020","unstructured":"Adnan SM, Khan S, Kazmi A, Bashir N, Siddique R (2020) COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J Adv Res 24:91\u201398","journal-title":"J Adv Res"},{"key":"22345_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","volume":"46","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani W, M\u00f8ller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L (2020) A Dzierba, B Du, Surviving sepsis campaign: guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 46:854\u2013887","journal-title":"Intensive Care Med"},{"key":"22345_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D (2016) Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 16:357\u2013365","journal-title":"Lancet Infect Dis"},{"key":"22345_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","volume":"13","author":"A Assiri","year":"2013","unstructured":"Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ (2013) Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13:752\u2013761","journal-title":"Lancet Infect Dis"},{"key":"22345_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF01309858","volume":"140","author":"B Ben-Nathan","year":"1995","unstructured":"Ben-Nathan B, Maestroni GJ, Lustig S, Conti A (1995) Protective effects of melatonin in mice infected with encephalitis viruses. Arch Virol 140:223\u2013230","journal-title":"Arch Virol"},{"key":"22345_CR6","first-page":"292","volume":"23","author":"HN Bernstein","year":"1991","unstructured":"Bernstein HN (1991) Ocular safety of hydroxychloroquine. Ann Ophthalmol 23:292\u2013296","journal-title":"Ann Ophthalmol"},{"key":"22345_CR7","doi-asserted-by":"publisher","first-page":"W252","DOI":"10.1093\/nar\/gku340","volume":"42","author":"M Biasini","year":"2014","unstructured":"Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Cassarino TG, Bertoni M, Bordoli L, Schwede T (2014) SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42:W252\u2013W258","journal-title":"Nucleic Acids Res"},{"key":"22345_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000024948","volume":"41","author":"NE Bishop","year":"1998","unstructured":"Bishop NE (1998) Practical guidelines in antiviral therapy. Intervirology 41:261\u2013271","journal-title":"Intervirology"},{"key":"22345_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising J, Polyak SJ, Pe\u0301cheur EI, (2014) Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107:84\u201394","journal-title":"Antiviral Res"},{"key":"22345_CR10","first-page":"512","volume":"68","author":"IE Blejan","year":"2020","unstructured":"Blejan IE, Diaconu CC, Leti\u021bia AN, Arsene DI, Ghica MA, Dr\u0103g\u0103nescu DO, Dragomiroiu GT, R\u0103dulescu M, Maltezou HC, Tsatsakis AM, Papasavva M (2020) Antibiotic resistance in community-acquired pneumonia. A Romanian Perspective Farmacia 68:512\u2013520","journal-title":"A Romanian Perspective Farmacia"},{"key":"22345_CR11","first-page":"637","volume":"52","author":"D Boda","year":"2018","unstructured":"Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE, Voiculescu V, Mamoulakis C (2018) Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol 52:637\u2013655","journal-title":"Int J Oncol"},{"key":"22345_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1386-6532(00)00140-2","volume":"20","author":"JR Boelaert","year":"2001","unstructured":"Boelaert JR, Piette J, Sperber K (2001) The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20:137\u2013140","journal-title":"J Clin Virol"},{"key":"22345_CR13","doi-asserted-by":"crossref","unstructured":"Ca\u0306lina D, Docea AO, Rosu L, Zlatian O, Rosu AF, Anghelina F, Rogoveanu O, Arsene AL, Nicolae AC, Dr\u0103goi CM, Tsiaoussis J (2017) Antimicrobial resistance development following surgical site infections. Mol Med Rep 15:681\u2013688","DOI":"10.3892\/mmr.2016.6034"},{"key":"22345_CR14","doi-asserted-by":"crossref","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X A (2020a) Trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. New Engl J Med 382:1787\u20131799","DOI":"10.1056\/NEJMoa2001282"},{"key":"22345_CR15","doi-asserted-by":"crossref","unstructured":"Cao W, Liu X, Bai T, Fan H, Hong K, Song H (2020b) High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 7:102","DOI":"10.1093\/ofid\/ofaa102"},{"key":"22345_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1164\/rccm.2014P7","volume":"201","author":"WG Carlos","year":"2020","unstructured":"Carlos WG, Dela CS, Cao B, Pasnick S, Jamil S (2020) Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med 201:7\u20138","journal-title":"Am J Respir Crit Care Med"},{"key":"22345_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2174\/1381612824666180426112832","volume":"24","author":"L Carrascal","year":"2018","unstructured":"Carrascal L, Nunez-Abades P, Ayala A, Cano M (2018) Role of melatonin in the inflammatory process and its therapeutic potential. Curr Pharm Design 24:1563\u20131588","journal-title":"Curr Pharm Design"},{"key":"22345_CR18","unstructured":"CDC (2020a) Novel Coronavirus (2019a-nCoV) Pregnant women. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/coronavirus\/2019a-ncov\/specificgroups\/pregnancy-faq.html. Accessed 19 Mar\u00a02020"},{"key":"22345_CR19","unstructured":"CDC (2020b) Novel Coronavirus (2019b-nCoV) Situation summary. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/coronavirus\/2019b-ncov\/summary.html.\u00a0Accessed 18 Mar\u00a02020"},{"key":"22345_CR20","unstructured":"CDC: Coronavirus Disease (2020c) (COVID-19): Interim Considerations for Infection Prevention and Control of Coronavirus Disease 2019a (COVID-19) in Inpatient Obstetric Healthcare Settings. CDC website. Updated February 27, 2020. Reviewed February 18, 2020.\u00a0https:\/\/www.cdc.gov\/coronavirus\/2019a-ncov\/hcp\/inpatient-obstetric-healthcare-guidance.html#anchor_1582067966715. Accessed 23 Mar 2020"},{"key":"22345_CR21","unstructured":"CDC: Coronavirus Disease (2020d) (COVID-19): Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019b Novel Coronavirus (2019b-nCoV). CDC website. Updated March 20, 2020. Reviewed March 20, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/guidance-home-care.html. Accessed 23 Mar\u00a02020"},{"key":"22345_CR22","unstructured":"Celularity (2020) Celularity announces FDA clearance of IND application for CYNK001 in coronavirus, first in cellular therapy. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04365101. Accessed 30 June 2020"},{"key":"22345_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ajem.2020.03.036","volume":"44","author":"S Chavez","year":"2020","unstructured":"Chavez S, Long B (2020) A Koyfman, SY Liang, Coronavirus disease (COVID-19): a primer for emergency physicians. Am J Emerg Med 44:220\u2013229","journal-title":"Am J Emerg Med"},{"key":"22345_CR24","doi-asserted-by":"crossref","unstructured":"Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, Chen Y, Wu JJ (2020a) First clinical study using HCV protease inhibitor danoprevir to treat naive and experienced COVID-19 patients. MedRxiv 99:e2357","DOI":"10.1101\/2020.03.22.20034041"},{"key":"22345_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T (2020b) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507\u2013513","journal-title":"Lancet"},{"key":"22345_CR26","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1378\/chest.129.6.1441","volume":"129","author":"RC Chen","year":"2006","unstructured":"Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, Zhong N (2006) Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 129:1441\u20131452","journal-title":"Chest"},{"key":"22345_CR27","unstructured":"Chictr.Org.Cn (2020a) Cancelled by the investigator randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild\/ common novel coronavirus pneumonia (COVID-19). Available at: http:\/\/www.chictr.org.cn\/showproj.aspx?proj=49915.Accessed Mar 15 2020a"},{"key":"22345_CR28","unstructured":"Chictr.Org.Cn (2020b) Clinical trial for recombinant human interleukin-2 in the treatment of novel coronavirus pneumonia (COVID-19). Available at: http:\/\/ www.chictr.org.cn\/showprojen.aspx?proj=49567. Accessed Feb 24 2020b"},{"key":"22345_CR29","unstructured":"Chictr.Org.Cn (2020d) A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19). Available at: http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49824. Accessed Feb 21 2020d"},{"key":"22345_CR30","unstructured":"Chictr.Org.Cn (2020e) A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19). Available at: http:\/\/www.chictr.org.cn\/historyversionpuben.aspx?regno=ChiCTR2000030424. Accessed May 14 2020e"},{"key":"22345_CR31","unstructured":"Clinicaltrials.Gov (2020a) Efficacy and safety of corticosteroids in COVID-19. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273321. Accessed May 11 2020a"},{"key":"22345_CR32","unstructured":"Clinicaltrials.Gov (2020b). Efficacy and safety of darunavir and cobicistat for treatment of COVID-19 (DC-COVID-19), Available at: https:\/\/clinicaltrials.Gov\/ct2\/show\/NCT04252274. Accessed Apr 13 2020b"},{"key":"22345_CR33","unstructured":"Clinicaltrials.Gov (2020c) The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID-19) pneumonia. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273529. Accessed Feb 21 2020c"},{"key":"22345_CR34","unstructured":"Clinicaltrials.Gov (2020d) Efficacy of addition of naproxen in the treatment of critically Ill patients hospitalized for COVID-19 infection (ENACOVID). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04325633. Accessed Apr 14 2020d"},{"key":"22345_CR35","unstructured":"Clinicaltrials.Gov (2020e) The efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02543567. Accessed Feb 7 2020e"},{"key":"22345_CR36","unstructured":"Clinicaltrials.Gov (2020f) Evaluating and comparing the safety and efficiency of ASC09\/ritonavir and lopinavir\/ritonavir for novel coronavirus infection. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261907 (Accessed 2020f Feb 10)"},{"key":"22345_CR37","unstructured":"Clinicaltrials.Gov (2020g) International ALLIANCE study of therapies to prevent progression of COVID-19. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04395768. Accessed May 20 2020g"},{"key":"22345_CR38","unstructured":"Clinicaltrials.Gov (2020h) The LEAD COVID-19 trial: low-risk, early aspirin and vitamin D to reduce COVID-19 hospitalizations (LEAD COVID-19). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363840. Accessed May 6 2020h"},{"key":"22345_CR39","unstructured":"Clinicaltrials.Gov (2020i) Leflunomide in mild COVID-19 patients. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04361214. Accessed May 11 2020i"},{"key":"22345_CR40","unstructured":"Clinicaltrials.Gov (2020j) LIBERATE Trial in COVID-19 (LIBERATE). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334629. Accessed May 1 2020j"},{"key":"22345_CR41","unstructured":"Clinicaltrials.Gov (2020k) Lopinavir\/ ritonavir, ribavirin and IFN-beta combination for nCoV treatment. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688. Accessed Apr 15 2020k"},{"key":"22345_CR42","unstructured":"Clinicaltrials.Gov (2020l) Natural Killer Cell (CYNK-001) Infusions in adults with COVID-19 (CYNK-001-COVID-19). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04365101. Accessed Apr 28 2020l"},{"key":"22345_CR43","unstructured":"Clinicaltrials.Gov (2020m) Post-exposure prophylaxis \/ preemptive therapy for SARScoronavirus-2 (COVID-19 PEP). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04308668. Accessed May 1 2020m"},{"key":"22345_CR44","unstructured":"Clinicaltrials.Gov (2020n) Randomized proof-of-concept trial to evaluate the safety and explore the effectiveness of resveratrol for COVID-19. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04400890. Accessed May 26 2020n"},{"key":"22345_CR45","unstructured":"Clinicaltrials.Gov (2020o). Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02735707. Accessed Apr 16 2020o"},{"key":"22345_CR46","unstructured":"Clinicaltrials.Gov (2020q) A study to evaluate the safety, pharmacokinetics and antiviral effects of galidesivir in yellow fever or COVID-19. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03891420. Accessed Apr 15 2020q"},{"key":"22345_CR47","unstructured":"Clinicaltrials.Gov (2020r) Trial to promote recovery from COVID-19 with ivermectin or endocrine therapy (RECOVER). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04374279. Accessed May 5 2020p"},{"key":"22345_CR48","unstructured":"Clinicaltrials.Gov (2020s) Vitamin C infusion for the treatment of severe 2019- nCoV infected pneumonia. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04264533 (Accessed 2020s Mar 10)"},{"key":"22345_CR49","unstructured":"Clinicaltrials.Gov (2020t) Administration of intravenous vitamin C in novel coronavirus infection (COVID-19) and decreased oxygenation (AVoCaDO). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04357782. Accessed Apr 22 2020q"},{"key":"22345_CR50","unstructured":"Clinicaltrials.Gov (2020u) Cholecalciferol to improve the outcomes of COVID-19 patients (CARED). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04411446. Accessed Jun 4 2020r"},{"key":"22345_CR51","unstructured":"Clinicaltrials.Gov (2020v) Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04286503 (Accessed the Clinical Study of Carrimycin on Treatment Patients with COVID-192020v Feb 27)"},{"key":"22345_CR52","unstructured":"Clinicaltrials.Gov (2020w) Clinical study to evaluate the performance and safety of favipiravir in COVID-19. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336904. Accessed Apr 8 2020s"},{"key":"22345_CR53","unstructured":"Clinicaltrials.Gov (2020x) Colchicine coronavirus SARS-CoV2 trial (COLCORONA) (COVID-19). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322682. Accessed 24 Apr\u00a02020"},{"key":"22345_CR54","unstructured":"Clinicaltrials.Gov (2020y) COvid-19 and vitamin D supplementation: a multicenter randomized controlled trial of high dose versus standard dose vitamin D3 in highrisk COVID-19 patients (CoVitTrial). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04344041. Accessed 6\u00a0May 2020"},{"key":"22345_CR55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2174\/187152710791011991","volume":"9","author":"GM Cole","year":"2010","unstructured":"Cole GM, Frautschy SA (2010) Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 9:140\u2013148","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"22345_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181\u2013192","journal-title":"Nat Rev Microbiol"},{"key":"22345_CR57","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/vbz.2008.0049","volume":"8","author":"XL De","year":"2008","unstructured":"De XL, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A et al (2008) On Chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 8:837\u2013840","journal-title":"Vector Borne Zoonotic Dis"},{"key":"22345_CR58","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","volume":"81","author":"L Deng","year":"2020","unstructured":"Deng L, Lia C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J (2020) Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study. J Infect 81:e1-5","journal-title":"J Infect"},{"key":"22345_CR59","doi-asserted-by":"crossref","unstructured":"Devaux CA, Rolain JM, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 55:105938","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"key":"22345_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J (2020) Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 14:58\u201360","journal-title":"Drug Discov Ther"},{"key":"22345_CR61","unstructured":"Dorward J, Gbinigie K (2020) Lopinavir\/ritonavir: a rapid review of effectiveness in COVID-19. 19"},{"key":"22345_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0959-440X(98)80089-4","volume":"8","author":"S Doublie","year":"1998","unstructured":"Doublie S, Ellenberger T (1998) The mechanism of action of T7 DNA polymerase. Curr Opin Struct Biol 8:704\u2013712","journal-title":"Curr Opin Struct Biol"},{"key":"22345_CR63","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1099\/jgv.0.000309","volume":"96","author":"SD Dowall","year":"2015","unstructured":"Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, Rayner E, Hunter L, Pearson G, Easterbrook L, Pitman J, Hewson R (2015) Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol 96:3484\u20133492","journal-title":"J Gen Virol"},{"key":"22345_CR64","doi-asserted-by":"publisher","first-page":"116958","DOI":"10.1016\/j.lfs.2019.116958","volume":"238","author":"AA Elfiky","year":"2019","unstructured":"Elfiky AA (2019) A Ismail, Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. Life Sci 238:116958","journal-title":"Life Sci"},{"key":"22345_CR65","doi-asserted-by":"publisher","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","volume":"248","author":"AA Elfiky","year":"2020","unstructured":"Elfiky AA (2020) Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 248:117477","journal-title":"Life Sci"},{"key":"22345_CR66","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jmv.24736","volume":"89","author":"AA Elfiky","year":"2017","unstructured":"Elfiky AA, Mahdy SM, Elsheme WM (2017) Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol 89:1040\u20131047","journal-title":"J Med Virol"},{"key":"22345_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxrep.2020.12.001","volume":"8","author":"K Farsalinos","year":"2021","unstructured":"Farsalinos K, Poulas K, Kouretas D, Vantarakis A, Leotsinidis M, Kouvelas D, Docea AO, Kostoff R, Gerotziafas GT, Antoniou MN, Polosa R, Barbouni A, Yiakoumaki V, Giannouchos TV, Bagos PG, Lazopoulos G, Izotov BN, Tutelyan VA, Aschner M, Hartung T, Wallace HM, Carvalho F, Domingo JL, Tsatsakis A (2021) Improved strategies to counter the COVID-19 pandemic: lockdowns vs. primary and community healthcare. Toxicol Rep 8:1\u20139. https:\/\/doi.org\/10.1016\/j.toxrep.2020.12.001","journal-title":"Toxicol Rep"},{"key":"22345_CR68","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Japan Acad Ser B 93:449\u2013463","journal-title":"Proc Japan Acad Ser B"},{"key":"22345_CR69","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72\u201373","journal-title":"Biosci Trends"},{"issue":"5","key":"22345_CR70","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2021.01.044","volume":"184","author":"ND Grubaugh","year":"2021","unstructured":"Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M (2021) Public health actions to control new SARS-CoV-2 variants. Cell 184(5):1127\u20131132","journal-title":"Cell"},{"key":"22345_CR71","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/1568026616666160824120338","volume":"17","author":"S Habtemariam","year":"2017","unstructured":"Habtemariam S, Daglia M, Sureda A, Selamoglu Z, Gulhan MF, Nabavi SM (2017) Melatonin and respiratory diseases: a review. Curr Top Med Chem 17:467\u2013488","journal-title":"Curr Top Med Chem"},{"key":"22345_CR72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","volume":"38","author":"C Harrison","year":"2020","unstructured":"Harrison C (2020) Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 38:379\u2013381","journal-title":"Nat Biotechnol"},{"key":"22345_CR73","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K (2018) Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 379:913\u2013923","journal-title":"N Engl J Med"},{"key":"22345_CR74","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929\u2013986","journal-title":"N Engl J Med"},{"key":"22345_CR75","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z (2020) Clinical features of patients infected with the 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506","journal-title":"Lancet"},{"key":"22345_CR76","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IFN Hung","year":"2020","unstructured":"Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP (2020) Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395:1695\u20131704","journal-title":"Lancet"},{"key":"22345_CR77","doi-asserted-by":"publisher","first-page":"12816","DOI":"10.1128\/JVI.00906-12","volume":"86","author":"J Huynh","year":"2012","unstructured":"Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, Nagel J, Johnson JB, Agnihothram S, Gates JE, Frieman MB (2012) Evidence sup porting a zoonotic origin of human coronavirus strain NL63. J Virol 86:12816\u201312825","journal-title":"J Virol"},{"key":"22345_CR78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","volume":"133","author":"Y Imai","year":"2008","unstructured":"Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YC, Wang H, Liu H (2008) Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133:235\u2013249","journal-title":"Cell"},{"key":"22345_CR79","doi-asserted-by":"publisher","first-page":"6","DOI":"10.31925\/farmacia.2020.6.3","volume":"68","author":"MT Islam","year":"2020","unstructured":"Islam MT, Salehi B, Karampelas O, Sharifi-Rad J, Docea AO, Martorell M, Calina D (2020) High skin melanin content, vitamin D deficiency and immunity: potential interference for severity of COVID-19. Farmacia 68:6. https:\/\/doi.org\/10.31925\/farmacia.2020.6.3","journal-title":"Farmacia"},{"key":"22345_CR80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.31925\/farmacia.2021.6.1","volume":"69","author":"MT Islam","year":"2021","unstructured":"Islam MT, Quispe C, Herrera-Bravo J, Khan I et al (2021) Possible mutation pathways in SARS-CoV-2. Farmacia 69:6. https:\/\/doi.org\/10.31925\/farmacia.2021.6.1","journal-title":"Farmacia"},{"key":"22345_CR81","doi-asserted-by":"publisher","unstructured":"Islam MT, Quispe C, Martorell M, Docea AO, Salehi B, Calina D, Reiner \u017d, Sharifi-Rad J (2021b) Dietary supplements, vitamins and minerals as potential interventions against viruses: perspectives for COVID-19. International J Vitam Nutr Res 92.\u00a0https:\/\/doi.org\/10.1024\/0300-9831\/a000694","DOI":"10.1024\/0300-9831\/a000694"},{"key":"22345_CR82","first-page":"877","volume":"65","author":"AM Kamal","year":"2017","unstructured":"Kamal AM, Mitru P, Docea AO, Sosoi SS, Kamal CK, Mitrut R, Margaritescu D, Calina D, Banciu C, Tica OS, Tica AA (2017) Double therapy with pegylated interferon and ribavirin for chronic hepatitis C. A pharmacogenetic guide for predicting adverse events. Farmacia 65:877\u2013884","journal-title":"Farmacia"},{"key":"22345_CR83","doi-asserted-by":"publisher","first-page":"11892","DOI":"10.1128\/JVI.79.18.11892-11900.2005","volume":"79","author":"B Kan","year":"2005","unstructured":"Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, Liang W, Zheng H, Wan K, Liu Q, Cui B (2005) Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol 79:11892\u201311900","journal-title":"J Virol"},{"key":"22345_CR84","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer RN, Ward AB (2019) Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 10:2342","journal-title":"Nat Commun"},{"key":"22345_CR85","doi-asserted-by":"crossref","unstructured":"Kronenberger P, Vrijsen R, Boey\u00e9 (1991) A chloroquine induces empty capsid formation during poliovirus eclipse. J Virol 65:7008\u20137011","DOI":"10.1128\/jvi.65.12.7008-7011.1991"},{"key":"22345_CR86","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1021\/bi035923w","volume":"43","author":"JJ Kwiek","year":"2004","unstructured":"Kwiek JJ, Haystead TA, Rudolph J (2004) Kinetic mechanism of quinine oxidoreductase 2 and its inhibition by the antimalarial quinolones. Biochemistry 43:4538\u20134547","journal-title":"Biochemistry"},{"key":"22345_CR87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1148\/radiol.2020200236","volume":"295","author":"J Lei","year":"2020","unstructured":"Lei J, Li J, Li X, Qi X (2020) CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 295:18\u201318","journal-title":"Radiology"},{"key":"22345_CR88","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia. N Engl J Med 382:1199\u20131207","journal-title":"N Engl J Med"},{"key":"22345_CR89","doi-asserted-by":"publisher","first-page":"105631","DOI":"10.1016\/j.ejps.2020.105631","volume":"57","author":"Y Lou","year":"2021","unstructured":"Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, Luo R, Yang X, He L, Lu X, Zhao Q (2021) Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci 57:105631","journal-title":"Eur J Pharm Sci"},{"key":"22345_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu H (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 14:69\u201371","journal-title":"Biosci Trends"},{"key":"22345_CR91","doi-asserted-by":"publisher","unstructured":"Mina F, Rahman M, Das S, Karmakar S, Billah M (2020) Potential drug candidates underway several registered clinical trials for battling COVID19. Authorea. https:\/\/doi.org\/10.22541\/au.158949149.99681139","DOI":"10.22541\/au.158949149.99681139"},{"key":"22345_CR92","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00535-009-0132-9","volume":"45","author":"T Mizui","year":"2010","unstructured":"Mizui T, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N et al (2010) Inhibition of hepatitis C virus replication by chloroquine targeting virusassociated autophagy. J Gastroenterol 45:195\u2013203","journal-title":"J Gastroenterol"},{"key":"22345_CR93","doi-asserted-by":"crossref","unstructured":"O\u2019hanlon R, Shaw ML (2019) Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol 35:14\u201318","DOI":"10.1016\/j.coviro.2019.01.006"},{"key":"22345_CR94","first-page":"115","volume":"42","author":"AR Parhizgar","year":"2017","unstructured":"Parhizgar AR, Tahghighi A (2017) Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iran J Med Sci 42:115\u2013128","journal-title":"Iran J Med Sci"},{"key":"22345_CR95","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","volume":"11","author":"NI Paton","year":"2011","unstructured":"Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, Wong G, Smith AW (2011) Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 11:677\u2013683","journal-title":"Lancet Infect Dis"},{"key":"22345_CR96","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1056\/NEJMc2001272","volume":"382","author":"LN Phan","year":"2020","unstructured":"Phan LN, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, Nguyen TT, Cao TM, Pham QD (2020) Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 382:872\u2013874","journal-title":"N Engl J Med"},{"key":"22345_CR97","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2105\/AJPH.2019.305186","volume":"109","author":"A Rahman","year":"2019","unstructured":"Rahman A, Sarkar A (2019) Risk factors for fatal Middle East respiratory syndrome coronavirus infections in Saudi Arabia: analysis of the WHO line list, 2013\u20132018. Am J Public Health 109:1288\u20131293","journal-title":"Am J Public Health"},{"key":"22345_CR98","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0042-6822(90)90099-D","volume":"174","author":"VB Randolph","year":"1990","unstructured":"Randolph VB, Winkler G, Stollar V (1990) Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450\u2013458","journal-title":"Virology"},{"key":"22345_CR99","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1128\/AAC.34.8.1512","volume":"34","author":"D Raoult","year":"1990","unstructured":"Raoult D, Drancourt M, Vestris G (1990) Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells. Antimicrob Agents Chemother 34:1512\u20131514","journal-title":"Antimicrob Agents Chemother"},{"key":"22345_CR100","doi-asserted-by":"publisher","first-page":"43","DOI":"10.32794\/mr11250047","volume":"3","author":"RJ Reiter","year":"2020","unstructured":"Reiter RJ, Ma Q, Sharma R (2020) Treatment of Ebola and other infectious diseases: melatonin \u201cgoes viral.\u201d Melatonin Res 3:43\u201357","journal-title":"Melatonin Res"},{"key":"22345_CR101","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/CM9.0000000000000722","volume":"133","author":"LL Ren","year":"2020","unstructured":"Ren LL, Wang YM, Wu ZQ (2020) Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Med J 133:1015\u20131024","journal-title":"Chinese Med J"},{"key":"22345_CR102","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304\u2013377","journal-title":"Intensive Care Med"},{"key":"22345_CR103","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395:e30\u2013e31","journal-title":"Lancet"},{"key":"22345_CR104","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-virology-092917-043515","volume":"5","author":"MC Rogers","year":"2018","unstructured":"Rogers MC, Williams JV (2018) Quis Custodiet Ipsos Custodes? Regulation of cell-mediated immune responses following viral lung infections. Annu Rev Virol 5:363\u2013383","journal-title":"Annu Rev Virol"},{"key":"22345_CR105","first-page":"2659","volume":"16","author":"OC Rogoveanu","year":"2018","unstructured":"Rogoveanu OC, Calina D, Cucu MG, Burada F, Docea AO, Sosoi S, Stefan E, Ioana M, Burada E (2018) Association of cytokine gene polymorphisms with osteoarthritis susceptibility. Exp Ther Med 16:2659\u20132664","journal-title":"Exp Ther Med"},{"key":"22345_CR106","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","volume":"109","author":"HA Rothan","year":"2020","unstructured":"Rothan HA, Byrareddy SN (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 109:102433","journal-title":"J Autoimmun"},{"key":"22345_CR107","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395:473\u2013475","journal-title":"Lancet"},{"key":"22345_CR108","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.18632\/aging.103001","volume":"12","author":"C Sargiacomo","year":"2020","unstructured":"Sargiacomo C, Sotgia F, Lisanti MP (2020) COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging 12:6511","journal-title":"Aging"},{"key":"22345_CR109","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3389\/fphar.2020.572870","volume":"11","author":"C Sarkar","year":"2020","unstructured":"Sarkar C, Mondal M, Islam MT, Martorell M, Docea AO, Maroyi A, Sharifi-Rad J, Calina D (2020) Potential therapeutic options for COVID-19: current status, challenges, and future perspectives. Front Pharmacol 11:1428","journal-title":"Front Pharmacol"},{"key":"22345_CR110","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00126334-200403010-00002","volume":"35","author":"A Savarino","year":"1996","unstructured":"Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, Tamburrini E, Perno CF, Boelaert JR, Sperber K, Cauda R (1996) Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35:223\u2013232","journal-title":"J Acquir Immune Defic Syndr"},{"key":"22345_CR111","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1111\/bph.15072","volume":"177","author":"C Scavone","year":"2020","unstructured":"Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F (2020) A Capuano, Current pharmacological treatments for COVID-19: What\u2019s next? Br J Pharmacol 177:4813\u20134824","journal-title":"Br J Pharmacol"},{"key":"22345_CR112","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Leist SR, Sch\u00e4fer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222","journal-title":"Nat Commun"},{"key":"22345_CR113","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3892\/ijmm.2020.4802","volume":"47","author":"P Sidiropoulou","year":"2020","unstructured":"Sidiropoulou P, Docea AO, Nikolaou V, Katsarou M-S, Spandidos DA et al (2020) Unraveling the roles of vitamin D status and melanin during Covid-19 (review). Int J Mol Med 47:92\u2013100","journal-title":"Int J Mol Med"},{"key":"22345_CR114","unstructured":"Smartpatients.Com (2020) A randomized multicenter controlled clinical trial of arbidol in patients with 2019 novel coronavirus (2019-nCoV). Available at: https:\/\/www.smartpatients.com\/trials\/NCT04246242 (Accessed 2020 Apr)"},{"key":"22345_CR115","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1023\/B:JOCI.0000010424.41475.17","volume":"23","author":"M Steiz","year":"2003","unstructured":"Steiz M, Valbracht J, Quach J, Lotz M (2003) Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 23:477\u2013484","journal-title":"J Clin Immunol"},{"key":"22345_CR116","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00024382-200204000-00005","volume":"17","author":"DY Tamura","year":"2002","unstructured":"Tamura DY, Moore EE, Partrick DA, Johnson JL, Offner PJ, Silliman CC (2002) Acute hypoxemia in humans enhances the neutrophil inflammatory response. Shock 17:269\u2013273","journal-title":"Shock"},{"key":"22345_CR117","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","volume":"72","author":"DH Tran","year":"2019","unstructured":"Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, Ito F, Yamamoto T, Kawachi S, Akagawa KS, \u014cmura S (2019) Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus infection by interfering with virus internalization process. J Antibiotics 72:759\u2013768","journal-title":"J Antibiotics"},{"key":"22345_CR118","doi-asserted-by":"publisher","first-page":"e785","DOI":"10.1371\/journal.pntd.0000785","volume":"4","author":"V Tricou","year":"2010","unstructured":"Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Hien TT, Simmons CP (2010) A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4:e785","journal-title":"PLoS Negl Trop Dis"},{"key":"22345_CR119","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/BF01310010","volume":"81","author":"H Tsiang","year":"1984","unstructured":"Tsiang H, Superti F (1984) Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells. Arch Virol 81:377\u2013382","journal-title":"Arch Virol"},{"key":"22345_CR120","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1096\/fasebj.11.4.9068613","volume":"11","author":"A Varki","year":"1997","unstructured":"Varki A (1997) Sialic acids as ligands in recognition phenomena. FASEB J 11:248\u2013255","journal-title":"FASEB J"},{"key":"22345_CR121","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69","journal-title":"Virol J"},{"key":"22345_CR122","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y (2020a) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China. JAMA 323:1061\u20131069","journal-title":"JAMA"},{"key":"22345_CR123","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271","journal-title":"Cell Res"},{"key":"22345_CR124","doi-asserted-by":"publisher","first-page":"e105617","DOI":"10.1371\/journal.pone.0105617","volume":"9","author":"RR Wang","year":"2021","unstructured":"Wang RR, Yang QH, Luo RH, Peng YM, Dai SX, Zhang XJ, Chen H, Cui XQ, Liu YJ, Huang JF, Chang JB (2021) Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS ONE 9:e105617","journal-title":"PLoS ONE"},{"key":"22345_CR125","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jmv.25689","volume":"92","author":"W Wang","year":"2020","unstructured":"Wang W, Tang J, Wei F (2020c) Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 92:441\u2013447","journal-title":"J Med Virol"},{"key":"22345_CR126","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y (2020d) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569\u20131578","journal-title":"Lancet"},{"key":"22345_CR127","unstructured":"WHO (2020a) Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. https:\/\/www.who.int\/publicationsdetail\/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected. WHO website. Updated March 13, 2020a. Accessed Mar 23, 2020b"},{"key":"22345_CR128","unstructured":"WHO (2020b) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe acute respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. Published January 28, 2020b. Accessed Mar 19 2020c"},{"key":"22345_CR129","unstructured":"WHO (2020c) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected, https:\/\/www.who.int\/publications-detail\/clinical-managementof-severe-acute-respiratory-infection-whennovel-coronavirus-(ncov)-infection-is-suspected. Accessed Jan 28 2020a"},{"key":"22345_CR130","doi-asserted-by":"crossref","unstructured":"Wu X, Ji H, Wang Y, Gu C, Gu W, Hu L, Zhu L (2019) Melatonin alleviates radiation-induced lung injury via regulation of miR 30e\/NLRP3 axis. Oxid Med Cell Longev 2019 2019:4087298","DOI":"10.1155\/2019\/4087298"},{"key":"22345_CR131","doi-asserted-by":"crossref","unstructured":"Zhang Q, Wang Y, Qi C, Shen L, Li J (2020a) Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol 92:540\u2013545","DOI":"10.1002\/jmv.25733"},{"key":"22345_CR132","doi-asserted-by":"publisher","first-page":"117583","DOI":"10.1016\/j.lfs.2020.117583","volume":"250","author":"R Zhang","year":"2018","unstructured":"Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ (2018) COVID-19: melatonin as a potential adjuvant treatment. Life Sci 250:117583","journal-title":"Life Sci"},{"key":"22345_CR133","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","volume":"214","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X (2020b) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol 214:108393","journal-title":"Clin Immunol"},{"key":"22345_CR134","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.01.050","volume":"92","author":"S Zhao","year":"2020","unstructured":"Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, Lou Y, Gao D, Yang L, He D, Wang MH (2020) Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis 92:214\u2013217","journal-title":"Int J Infect Dis"},{"key":"22345_CR135","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","volume":"362","author":"N Zhong","year":"2003","unstructured":"Zhong N, Zheng B, Li Y, Poon L, Xie Z, Chan K, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ (2003) Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003. Lancet 362:1353\u20131358","journal-title":"Lancet"},{"key":"22345_CR136","first-page":"270","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD (2020) Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. BioRxiv 579:270\u2013273","journal-title":"BioRxiv"},{"key":"22345_CR137","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMc2001737","volume":"382","author":"L Zou","year":"2020","unstructured":"Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177\u20131179","journal-title":"N Engl J Med"}],"container-title":["Environmental Science and Pollution Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-22345-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11356-022-22345-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-022-22345-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T19:20:34Z","timestamp":1666552834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11356-022-22345-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":137,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["22345"],"URL":"https:\/\/doi.org\/10.1007\/s11356-022-22345-w","relation":{},"ISSN":["0944-1344","1614-7499"],"issn-type":[{"value":"0944-1344","type":"print"},{"value":"1614-7499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors have approved the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}